Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Melanoma drug combo tested in everyday practice

NCT ID NCT04961619

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how well the combination of dabrafenib and trametinib works in real-life settings for people with high-risk stage III melanoma that has been completely removed by surgery. It included 39 adults in Turkey whose melanoma had a specific genetic mutation (V600E). The main goal was to see how long patients stayed cancer-free after starting treatment. This was an observational study, meaning researchers did not give the drugs but simply collected data from routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

39 people

The number who actually took part.

Started

Dec 2021

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Completely resected high-risk stage III melanoma patients treated with dabrafenib and trametinib in the adjuvant setting

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with complete surgical resection of histologically confirmed AJCC (8th edition) clinical stage III (stage IIIA \[lymph node \> 1mm\],, IIIB, IIIC, IIID) melanoma, in whom a decision for adjuvant treatment with dabrafenib and trametinib has been made before entering the study; * V600E mutation-positive cutaneous melanoma; * ≥ 18 years of age; * Written informed consent signed. Exclusion Criteria: * Lack of basic demographic and staging data. * Current active participation in an interventional clinical trial for treatment of melanoma. * Pregnancy or breastfeeding women. * Current primary diagnosis of a cancer other than melanoma, that requires systemic or other treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma

Contacts and locations

Locations

  • Novartis Investigative Site

    Antalya, Konyaalti, 07070, Turkey (Türkiye)

  • Novartis Investigative Site

    Edirne, Merkez, 22030, Turkey (Türkiye)

  • Novartis Investigative Site

    Bursa, Nilufer, 16059, Turkey (Türkiye)

  • Novartis Investigative Site

    Diyarbakır, Sur, 21280, Turkey (Türkiye)

  • Novartis Investigative Site

    Istanbul, Uskudar, 34668, Turkey (Türkiye)

  • Novartis Investigative Site

    Adana, Yuregir, 1230, Turkey (Türkiye)

  • Novartis Investigative Site

    Ankara, 06520, Turkey (Türkiye)

  • Novartis Investigative Site

    Izmir, 35100, Turkey (Türkiye)

  • Novartis Investigative Site

    Kecioren Ankara, 06010, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.